New option for primary stroke prevention in sickle cell anaemia. DeBaun MR, Kirkham FJ (2016) Lancet 387: 626-627 Cid13 is a cytoplasmic poly(A) polymerase that regulates ribonucleotide reductase mRNA. Saitoh S, Chabes A, McDonald WH, Thelander L, Yates JR, Russell P (2002) Cell 109: 563-73 The challenge of creating an evidence-based guideline for sickle cell disease. DeBaun MR (2014) JAMA 312: 1004-5 Constraining G1-specific transcription to late G1 phase: the MBF-associated corepressor Nrm1 acts via negative feedback. de Bruin RA, Kalashnikova TI, Chahwan C, McDonald WH, Wohlschlegel J, Yates J, Russell P, Wittenberg C (2006) Mol Cell 23: 483-96 Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, Donehower LA, Elledge SJ (2000) Genes Dev 14: 1448-59 The Schizosaccharomyces pombe cdc5+ gene encodes an essential protein with homology to c-Myb. Ohi R, McCollum D, Hirani B, Den Haese GJ, Zhang X, Burke JD, Turner K, Gould KL (1994) EMBO J 13: 471-83 Dpb11 activates the Mec1-Ddc2 complex. Mordes DA, Nam EA, Cortez D (2008) Proc Natl Acad Sci U S A 105: 18730-4 Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Weissman SB, Sinclair GI, Green CL, Fissell WH (1999) Clin Infect Dis 29: 223-4 Proapoptotic Bid mediates the Atr-directed DNA damage response to replicative stress. Liu Y, Bertram CC, Shi Q, Zinkel SS (2011) Cell Death Differ 18: 841-52 Bid protects the mouse hematopoietic system following hydroxyurea-induced replicative stress. Liu Y, Aiello A, Zinkel SS (2012) Cell Death Differ 19: 1602-12 Cyclin-dependent kinase 9-cyclin K functions in the replication stress response. Yu DS, Zhao R, Hsu EL, Cayer J, Ye F, Guo Y, Shyr Y, Cortez D (2010) EMBO Rep 11: 876-82 Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model. Lebensburger JD, Pestina TI, Ware RE, Boyd KL, Persons DA (2010) Haematologica 95: 1599-603 A novel class of mutations that affect DNA replication in E. coli. Nordman J, Skovgaard O, Wright A (2007) Mol Microbiol 64: 125-38 Prospects for primary stroke prevention in children with sickle cell anaemia. Jordan LC, Casella JF, DeBaun MR (2012) Br J Haematol 157: 14-25 Hydroxycarbamide and white matter integrity in pediatric sickle cell disease: Commentary to accompany: Hydroxycarbamide treatment in children with sickle cell anaemia is associated with more intact white matter integrity: a quantitative MRI study. Lance EI, Jordan LC (2019) Br J Haematol 187: 141-143 Rapid activation of ATR by ionizing radiation requires ATM and Mre11. Myers JS, Cortez D (2006) J Biol Chem 281: 9346-50 Multiple protein kinases influence the redistribution of fission yeast Clp1/Cdc14 phosphatase upon genotoxic stress. Broadus MR, Gould KL (2012) Mol Biol Cell 23: 4118-28 Hydroxyurea as secondary prevention for stroke in children with sickle cell anemia. DeBaun MR (2005) J Pediatr 147: 560-1 Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Galadanci NA, Umar Abdullahi S, Vance LD, Musa Tabari A, Ali S, Belonwu R, Salihu A, Amal Galadanci A, Wudil Jibir B, Bello-Manga H, Neville K, Kirkham FJ, Shyr Y, Phillips S, Covert BV, Kassim AA, Jordan LC, Aliyu MH, DeBaun MR (2017) Am J Hematol 92: 780-788 Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years. Chaturvedi S, DeBaun MR (2016) Am J Hematol 91: 5-14 Mutation of serine 1333 in the ATR HEAT repeats creates a hyperactive kinase. Luzwick JW, Nam EA, Zhao R, Cortez D (2014) PLoS One 9: e99397 The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. Kassim AA, DeBaun MR (2014) Expert Opin Pharmacother 15: 325-36 Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial. Galadanci NA, Abdullahi SU, Tabari MA, Abubakar S, Belonwu R, Salihu A, Neville K, Kirkham F, Inusa B, Shyr Y, Phillips S, Kassim AA, Jordan LC, Aliyu MH, Covert BV, DeBaun MR (2015) Pediatr Blood Cancer 62: 395-401 Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia. Ghafuri DL, Chaturvedi S, Rodeghier M, Stimpson SJ, McClain B, Byrd J, DeBaun MR (2017) Pediatr Blood Cancer 64: Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis. Patel NG, Lindsey T, Strunk RC, DeBaun MR (2010) Pediatr Blood Cancer 55: 554-6 Exploring barriers and facilitators to clinical trial enrollment in the context of sickle cell anemia and hydroxyurea. Lebensburger JD, Sidonio RF, Debaun MR, Safford MM, Howard TH, Scarinci IC (2013) Pediatr Blood Cancer 60: 1333-7 Stroke Recurrence in Nigerian Children With Sickle Cell Disease: Evidence for a Secondary Stroke Prevention Trial. Abdullahi SU, DeBaun MR, Jordan LC, Rodeghier M, Galadanci NA (2019) Pediatr Neurol 95: 73-78
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.